KLRK1 and neoplasm: Additionally, NKG2D CAR-T can kill immunosuppressive myeloid-derived suppressor cells and regulatory T cells, as well as tumor neovasculature expressing NKG2D ligands, thereby overcoming the immunosuppressive tumor microenvironment (TME) and increasing immunotherapy efficacy (26).